Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24285875 | 0.85 | DHFR (0.37) | USP7LRRK2DHFRPARP10PARP11 | |
| SCHEMBL24285966 | 0.84 | MAP4K1 (0.34) | USP7NPC1ALDH1A1RAB9A | |
| SCHEMBL24285941 | 0.80 | TDO2 (0.33) | ALDH1A1 | |
| SCHEMBL24286081 | 0.79 | PIM1 (0.30) | — | |
| SCHEMBL24285859 | 0.78 | CA12 (0.45) | NPC1LRRK2 | |
| SCHEMBL29537609 | 0.76 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL29538083 | 0.76 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL29537521 | 0.76 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL29537398 | 0.76 | LRRK2 (0.42) | LRRK2 | |
| SCHEMBL24285948 | 0.75 | MAP3K14 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | 1ST Biotherapeutics, Inc. (KR) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087985-A1 | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS | NLRP3, NLRP1, KCNJ2 | USP7 4519/4885NPC1 1816/4885ALDH1A1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.